HomeCompanyTechnologyPipelinePatientsInvestors & MediaCareersContact
Back to Investors & Media

May 8, 2021


May 8, 2021

Scientific Founder, Prof Antonio Bertoletti Appointed in Cell and Gene Therapy Workgroup in Singapore

SINGAPORE – May 08, 2021– Lion TCR is pleased to announce that Scientific Founder & Chairman, Professor Antonio Bertoletti has been appointed as a Technical Panel member of the Cell and Gene Therapy (CGT) Workgroup in Singapore. Congratulations to Prof Antonio Bertoletti on his new appointment.  

Cell and Gene Therapy has been identified as a priority area for Singapore. CGT Workgroup is set up by National Research Foundation (NRF) to help shape Singapore national research, innovation and enterprise (RIE) 2025 strategy in the area of cell and gene therapy. The technical panel will perform a global competitive analysis of the CGT research & innovation landscape and identify priority areas for Singapore. This will help differentiate Singapore and enhance its competitiveness. The technical panel will help advise and propose a national strategy to guide CGT research & innovation to position Singapore as a leading hub that transforms and protects health and create economic value through excellence in its CGT research and applications.